

Author Index Volume 15 (2002)

The issue number is given in front of the page numbers.

- Bell, A., see Medawar, C. (3,4) 161–169
Bjeldbak-Olesen, I., see Bourke, J. (3,4) 183–191
Bourke, J., I. Bjeldbak-Olesen, P.M. Nielsen and L.K. Munck, Shared charts for prescription and administration: Increasing safety of drug treatment (3,4) 183–191
Bowman, D., see Poloniecki, J. (3,4) 171–182

Causse, R., see Saizy-Callaert, S. (3,4) 193–202
Chapman, S., Chapter 13: Experiences with professional education (1,2) 119–125
Chouaïd, C., see Saizy-Callaert, S. (3,4) 193–202

de Joncheere, K., F.M. Haaijer-Ruskamp, A.D. Rietveld and M.N.G. Dukes, Chapter 1: Scope of the problem (1,2) 7– 13
de Joncheere, K. and T. Paal, Chapter 14: Providing affordable medicines in transitional countries (1,2) 127–135
de Joncheere, K., A.H. Rietveld and C. Huttin, Chapter 11: Experiences with generics (1,2) 101–109
Dufay, E., see Lepaux, D.J. (3,4) 203–211
Duke, K.S., see Lipton, H.L. (1,2) 111–118
Dukes, M.N.G., see de Joncheere, K. (1,2) 7– 13

Everard, M., Chapter 15: Access to medicines in low-income countries (1,2) 137–149

Haaijer-Ruskamp, F.M., Chapter 9: Experiences with patient charges (1,2) 93– 96
Haaijer-Ruskamp, F.M., see de Joncheere, K. (1,2) 7– 13
Haaijer-Ruskamp, F.M., see Rietveld, A.H. (1,2) 29– 54
Herxheimer, A., see Medawar, C. (3,4) 161–169
Huttin, C., Chapter 7: Experiences with budgets (1,2) 81– 84
Huttin, C., Chapter 8: Experiences with reference pricing (1,2) 85– 91
Huttin, C., see de Joncheere, K. (1,2) 101–109

Jofre, S., see Medawar, C. (3,4) 161–169

Lepaux, D.J., E. Schmitt and E. Dufay, Fighting medication errors: Results of a study and reflections on causes and ways for prevention (3,4) 203–211
Lexchin, J., Should doctors be prescribing new drugs? (3,4) 213–222
Lipton, H.L. and K.S. Duke, Chapter 12: Experiences with pharmacy benefit management programmes in the USA (1,2) 111–118

McDaid, D., E. Mossialos and M.F. Mrazek, Chapter 5: Making use of economic evaluation (1,2) 67– 74
Medawar, C., A. Herxheimer, A. Bell and S. Jofre, Paroxetine, *Panorama* and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance (3,4) 161–169

- Mitchell, A.S., Chapter 6: Measures relating to use of drug subsidy lists and to regulation (1,2) 77– 79
- Mossialos, E. and M.F. Mrazek, Chapter 2: Data needed for developing and monitoring policies (1,2) 15– 27
- Mossialos, E., see McDaid, D. (1,2) 67– 74
- Mossialos, E., see Mrazek, M.F. (1,2) 55– 66
- Mrazek, M.F. and E. Mossialos, Chapter 4: Methods for monitoring and evaluating processes and outcomes (1,2) 55– 66
- Mrazek, M.F., see McDaid, D. (1,2) 67– 74
- Mrazek, M.F., see Mossialos, E. (1,2) 15– 27
- Munck, L.K., see Bourke, J. (3,4) 183–191
- Nielsen, P.M., see Bourke, J. (3,4) 183–191
- Noyce, P.R., Chapter 10: Switching to non-prescription status (1,2) 97– 99
- Paal, T., see de Joncheere, K. (1,2) 127–135
- Poloniecki, J. and D. Bowman, New legislation is required if patients are to be adequately informed of the risks of surgery (3,4) 171–182
- Rietveld, A.D., see de Joncheere, K. (1,2) 7– 13
- Rietveld, A.H. and F.M. Haaijer-Ruskamp, Chapter 3: Policy options for cost containment of pharmaceuticals (1,2) 29– 54
- Rietveld, A.H., see de Joncheere, K. (1,2) 101–109
- Saizy-Callaert, S., R. Causse, A. Thébault and C. Chouaïd, Failure Mode, Effects and Criticality Analysis (FMECA) as a means of improving the hospital drug prescribing process (3,4) 193–202
- Schmitt, E., see Lepaux, D.J. (3,4) 203–211
- Thébault, A., see Saizy-Callaert, S. (3,4) 193–202